Skip to main content
Erschienen in: Medical Molecular Morphology 4/2016

30.06.2015 | Original Paper

ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors

verfasst von: Shogo Tajima, Yuichi Takashi, Nobuaki Ito, Seiji Fukumoto, Masashi Fukuyama

Erschienen in: Medical Molecular Morphology | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Phosphaturic mesenchymal tumors (PMT) are the most common cause of tumor-induced osteomalacia (TIO) related to mesenchymal neoplasms. The lineage of differentiation of PMTs has not been elucidated in existing literature. Fourteen cases of PMT were analyzed for this study to elucidate its lineage. We used vascular and/or lymphatic endothelial markers for the immunohistochemical analysis, which included CD31, CD34, factor VIII-related antigen, podoplanin, Freund’s leukemia integration site 1 (FLI1), and avian v-ets erythroblastosis virus E26 oncogene homolog (ERG). FLI1 and ERG were stained in all cases with proportion of immunopositive tumor cells largely more than 50 %; staining intensity was moderate or strong for both FLI1 and ERG. The tumor cells were stained with CD31 and/or CD34, with significantly less staining than observed for FLI1 and ERG. The tumor cells were completely immunonegative for factor VIII-related antigen and podoplanin. FLI1 and ERG are known to have considerable specificity to endothelial cells; ERG is more widely equipped in surgical pathology laboratories than FLI1. We concluded that ERG (or FLI1 if available) is useful marker for the diagnosis of PMT, and that PMTs may have an endothelial cell lineage.
Literatur
2.
Zurück zum Zitat Nakahama H, Nakanishi T, Uno H, Takaoka T, Taji N, Uyama O, Kitada O, Sugita M, Miyauchi A, Sugishita T et al (1995) Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int 55(1):38–40CrossRefPubMed Nakahama H, Nakanishi T, Uno H, Takaoka T, Taji N, Uyama O, Kitada O, Sugita M, Miyauchi A, Sugishita T et al (1995) Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int 55(1):38–40CrossRefPubMed
3.
Zurück zum Zitat Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O’Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28(1):1–30CrossRefPubMed Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jan de Beur SM, Mentzel T, Montgomery E, Michal M, Miettinen M, Mills SE, Reith JD, O’Connell JX, Rosenberg AE, Rubin BP, Sweet DE, Vinh TN, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28(1):1–30CrossRefPubMed
4.
Zurück zum Zitat Folpe AL (2013) phosphaturic mesenchymal tumour. WHO classification of tumours of soft tissue and bone. IARC, Lyon Folpe AL (2013) phosphaturic mesenchymal tumour. WHO classification of tumours of soft tissue and bone. IARC, Lyon
7.
Zurück zum Zitat Westra WH, Gerald WL, Rosai J (1994) Solitary fibrous tumor. consistent CD34 immunoreactivity and occurrence in the orbit. Am J Surg Pathol 18(10):992–998CrossRefPubMed Westra WH, Gerald WL, Rosai J (1994) Solitary fibrous tumor. consistent CD34 immunoreactivity and occurrence in the orbit. Am J Surg Pathol 18(10):992–998CrossRefPubMed
8.
Zurück zum Zitat Miettinen M, Lindenmayer AE, Chaubal A (1994) Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens–evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 7(1):82–90PubMed Miettinen M, Lindenmayer AE, Chaubal A (1994) Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens–evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 7(1):82–90PubMed
9.
Zurück zum Zitat Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154(2):385–394. doi:10.1016/s0002-9440(10)65285-6 CrossRefPubMedPubMedCentral Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154(2):385–394. doi:10.​1016/​s0002-9440(10)65285-6 CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Folpe AL, Chand EM, Goldblum JR, Weiss SW (2001) Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol 25(8):1061–1066CrossRefPubMed Folpe AL, Chand EM, Goldblum JR, Weiss SW (2001) Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. Am J Surg Pathol 25(8):1061–1066CrossRefPubMed
11.
Zurück zum Zitat Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S, Sesterhenn I (2011) ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 35(3):432–441. doi:10.1097/PAS.0b013e318206b67b CrossRefPubMed Miettinen M, Wang ZF, Paetau A, Tan SH, Dobi A, Srivastava S, Sesterhenn I (2011) ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma. Am J Surg Pathol 35(3):432–441. doi:10.​1097/​PAS.​0b013e318206b67b​ CrossRefPubMed
12.
Zurück zum Zitat Sato Y (2001) Role of ETS family transcription factors in vascular development and angiogenesis. Cell Struct Funct 26(1):19–24CrossRefPubMed Sato Y (2001) Role of ETS family transcription factors in vascular development and angiogenesis. Cell Struct Funct 26(1):19–24CrossRefPubMed
15.
Zurück zum Zitat Morais CL, Han JS, Gordetsky J, Nagar MS, Anderson AE, Lee S, Hicks JL, Zhou M, Magi-Galluzzi C, Shah RB, Epstein JI, De Marzo AM, Lotan TL (2015) Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am J Surg Pathol 39(2):169–178. doi:10.1097/pas.0000000000000348 CrossRefPubMedPubMedCentral Morais CL, Han JS, Gordetsky J, Nagar MS, Anderson AE, Lee S, Hicks JL, Zhou M, Magi-Galluzzi C, Shah RB, Epstein JI, De Marzo AM, Lotan TL (2015) Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy. Am J Surg Pathol 39(2):169–178. doi:10.​1097/​pas.​0000000000000348​ CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Tomlins SA, Palanisamy N, Brenner JC, Stall JN, Siddiqui J, Thomas DG, Lucas DR, Chinnaiyan AM, Kunju LP (2013) Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. Am J Clin Pathol 139(6):771–779. doi:10.1309/ajcpn4l1bmrqpeit CrossRefPubMedPubMedCentral Tomlins SA, Palanisamy N, Brenner JC, Stall JN, Siddiqui J, Thomas DG, Lucas DR, Chinnaiyan AM, Kunju LP (2013) Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. Am J Clin Pathol 139(6):771–779. doi:10.​1309/​ajcpn4l1bmrqpeit​ CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat van de Rijn M, Lombard CM, Rouse RV (1994) Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung. Am J Surg Pathol 18(8):814–820CrossRefPubMed van de Rijn M, Lombard CM, Rouse RV (1994) Expression of CD34 by solitary fibrous tumors of the pleura, mediastinum, and lung. Am J Surg Pathol 18(8):814–820CrossRefPubMed
19.
Zurück zum Zitat Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, Ranchere-Vince D, Decouvelaere AV, de la Fouchardiere A, Gill AJ (2013) Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol 44(12):2711–2718. doi:10.1016/j.humpath.2013.07.016 CrossRefPubMed Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, Ranchere-Vince D, Decouvelaere AV, de la Fouchardiere A, Gill AJ (2013) Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol 44(12):2711–2718. doi:10.​1016/​j.​humpath.​2013.​07.​016 CrossRefPubMed
21.
Zurück zum Zitat Portela-Gomes GM, Hacker GW, Weitgasser R (2004) Neuroendocrine cell markers for pancreatic islets and tumors. Appl Immunohistochem Mol Morphol 12(3):183–192CrossRefPubMed Portela-Gomes GM, Hacker GW, Weitgasser R (2004) Neuroendocrine cell markers for pancreatic islets and tumors. Appl Immunohistochem Mol Morphol 12(3):183–192CrossRefPubMed
Metadaten
Titel
ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors
verfasst von
Shogo Tajima
Yuichi Takashi
Nobuaki Ito
Seiji Fukumoto
Masashi Fukuyama
Publikationsdatum
30.06.2015
Verlag
Springer Japan
Erschienen in
Medical Molecular Morphology / Ausgabe 4/2016
Print ISSN: 1860-1480
Elektronische ISSN: 1860-1499
DOI
https://doi.org/10.1007/s00795-015-0115-2

Weitere Artikel der Ausgabe 4/2016

Medical Molecular Morphology 4/2016 Zur Ausgabe

Neu im Fachgebiet Pathologie